Coronavirus: India’s second vaccine gets approval for two phases of human trials

Henrietta Strickland
July 3, 2020

Shares of Cadila Healthcare climbed almost 5 per cent in Friday's trade after the Ahmedabad-based company received a nod from the Drugs Controller General of India (DCGI) for human clinical trials of an indigenously developed Covid 19 vaccine.

The company said in a statement that its vaccine was found to elicit a "strong immune response" in mice, rats, guinea pigs and rabbits. Precisely, there are almost 150 vaccine candidates under development now, of which 17 are undergoing human trials. "The antibodies produced by the vaccine were able to completely neutralize the wild type virus in virus neutralization assay indicating the protective potential of the vaccine candidate", Zydus Cadila said.

There were no safety concerns for the vaccine candidate in repeat dose toxicology studies, Zydus said.

The company is expected to begin human trials this month in over 1,000 subjects in multiple sites in India.

Follow today's updates on the coronavirus pandemic. Trials would also be conducted at the AIIMS, Delhi and Hyderabad.

The letter has directed selected groups which has been chosen as a clinical trial site informing them that all approvals related to initiation of the clinical trial should be fast tracked and that "non-compliance will be viewed very seriously".

If this target is met and the vaccine is cleared for emergency public use by August 15, it would be a major scientific record. With these new cases, India's coronavirus tally has risen to 625,544 cases of which 227,439 patients are active cases while 379,892 patients have been cured/discharged/migrated. The country's overall count rose to 6,25,544 and the toll reached 18,213.

Vaccine What we know about this vaccine?

University of Oxford's vaccine is the furthest in the trial, now in the third phase, while there are various candidates in the second phase. The World Health Organization, however, had said last month that United Kingdom-based pharma firm AstraZeneca's experimental vaccine was probably the leading candidate.

Other reports by Click Lancashire

Discuss This Article